Data from Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
Pablo D. García, Matthew T. Burger(Novartis (Switzerland)), Jamie Narberes(Novartis (Switzerland)), Tatiana Zavorotinskaya(Novartis (Switzerland)), Joseph Castillo, Christine Fritsch, Stephen E. Basham(Therapeutics Clinical Research), Mika Lindvall, Marjorie Ison(Novartis (Switzerland)), J. Alex Aycinena, Yingyun Wang(Revolution Medicines (United States)), Paul Feucht(Novartis (United States)), Robert Warne(Novartis (Switzerland)), Michael P. Doyle(Agri Food and Biosciences Institute), Joerg Trappe(Novartis (Switzerland)), Peter Drueckes(Novartis (Switzerland)), Estelle Pfister(Novartis (Switzerland)), Jocelyn Holash(Regeneron (United States)), Julie Y.H. Chan(The Alfred Hospital), Wooseok Han, Cornelia Bellamacina, Tiffany Tsang(Novartis (United States)), Christie Fanton(Nektar Therapeutics (United States)), Min Chen(Novartis (Switzerland)), Jing Lu(The Affiliated Yongchuan Hospital of Chongqing Medical University), Christopher Wilson(University of Washington), Jianjun Yu, Jiong Lan(Novartis (Switzerland)), Yumin Dai(Robert Bosch (Germany)), Xiaohong Niu, John L. Langowski(Novartis (Switzerland)), Richard Zang(Genesys (United States)), Audrey Kauffmann(Novartis (Switzerland)), Gisele Nishiguchi(St. Jude Children's Research Hospital)
Cited by 0
Related Papers
Initial sequencing and analysis of the human genome
|Nature|2001|24.6k
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k